Table 1.

Demographics of the healthy controls and demographics, clinical history, and clinical features of the subgroup of 62 patients with IgA nephropathy provided with complete data set

Healthy controls
    number69
    gender (men/women)48/21 (70%/30%)
    ethnicity (Caucasian/African American/Asian)62/3/4 (90%/4%/6%)
IgAN patients
    number62
    gender (men/women)44/18 (71%/29%)
    ethnicity (Caucasian/African American/Asian)256/15/21 (88%/5%/7%)
    pediatric at time of biopsy (<18 years)47%
At sampling
    time elapsed since renal biopsy (years)4.3 (IQR 2.4 to 7.5)
    age (years)18.7 (IQR 13.7 to 22.3)
    eGFR (ml/min per 1.73 m2)100.6 (IQR 85.7 to 119.4)
    stage 1, 2, 3, 4, 5 CKD (DOQI)66%, 23%, 8%, 3%, 0%
    proteinuria (g/d)1.03 (IQR 0.31 to 1.59)
Follow-up
    duration of follow-up (years)4.46 ± 1.53
    50% decline in renal functionNo patient
    stage 1, 2, 3, 4, 5 CKD (DOQI) at the end of follow-up61%, 26%, 9%, 2.4%, 1.6%
    rate of renal function decline (ml/min per 1.73 m2/yr)−0.75 ± 6.1
    time-average proteinuria (g/d)0.73 (IQR 0.3 to 1.7)
  • In these patients, we assessed the relationships between the investigated biomarkers and clinical features at sampling and during follow-up. Values are expressed as mean ± SD or median (IQR). Calculations of eGFR are detailed in Materials and Methods. CKD stages were determined based on eGFR according to KDOQI guidelines. CKD, chronic kidney disease; eGFR, estimated GFR; IQR, interquartile range.